Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 17/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.92 |
| ▸ | CTSD | P07339 | 1/20 | 0.64 |
| ▸ | CTSE | P14091 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL5941575 | 0.97 | REN (0.87) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5941603 | 0.92 | REN (0.77) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5942218 | 0.91 | CYP3A4 (0.77) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5942086 | 0.90 | REN (0.75) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5942318 | 0.89 | REN (0.76) | RENCYP3A4 | |
| Formic Acid SCHEMBL5942110 | 0.89 | REN (0.73) | RENCYP3A4CTSDCTSE | |
| Formic Acid SCHEMBL5942204 | 0.89 | CYP3A4 (0.73) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5941780 | 0.88 | REN (0.75) | RENCYP3A4 | |
| SCHEMBL5941914 | 0.88 | REN (0.72) | RENCYP3A4 | |
| SCHEMBL5941689 | 0.88 | CYP3A4 (0.76) | RENCYP3A4CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-12 | — | — | US | claimed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | claimed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | claimed |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-12 | — | — | US | disclosed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | REN, ACE, ACE2 | REN 1/4885CYP3A4 181/4885CTSD 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.